Clinical Trial

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.
Trial Details
NCT Number NCT06947226
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Solid Tumors
Enrollment 188 participants
Start Date 2025-04
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-04-27